SSY Group (SEHK:2005) - Prezzo delle azioni, notizie e analisi

2005 Panoramica delle azioni

2005 analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	2/6
Prestazioni passate	5/6
Salute finanziaria	5/6
Dividendi	3/6

Premi

Negoziato a 61.4% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 5.81% all'anno

Gli utili sono cresciuti del 14.6% nell'ultimo anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Il dividendo di 4.76% non è ben coperto dai flussi di cassa liberi

SSY Group Limited Concorrenti

Luye Pharma Group

SEHK:2186

HK$10.1b

Shandong Xinhua Pharmaceutical

SEHK:719

HK$9.6b

China Traditional Chinese Medicine Holdings

SEHK:570

HK$11.6b

Grand Pharmaceutical Group

SEHK:512

HK$16.1b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per SSY Group
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$3.78
Massimo di 52 settimane	HK$5.20
Minimo di 52 settimane	HK$3.31
Beta	0.62
1Variazione di 1 mese	-4.55%
Variazione a 3 mesi	6.48%
Variazione di 1 anno	-22.86%
3Variazione a 3 anni	-2.58%
Variazione a 5 anni	-39.90%
Variazione dall'IPO	886.09%

Notizie e aggiornamenti recenti

Recent updates

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Mar 28

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

Mar 06

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Feb 13

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

Dec 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Sep 26

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07

Sep 03

If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity

Aug 31

Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Jun 24

Rendimenti per gli azionisti

	2005	HK Pharmaceuticals	HK Mercato
7D	-2.1%	-2.0%	-2.7%
1Y	-22.9%	-9.4%	10.9%

Ritorno vs Industria: 2005 ha avuto una performance inferiore rispetto al Hong Kong Pharmaceuticals che ha registrato un rendimento -9.4 % nell'ultimo anno.

Rendimento vs Mercato: 2005 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 10.9 % nell'ultimo anno.

Volatilità dei prezzi

Is 2005's price volatile compared to industry and market?
2005 volatility
2005 Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

Prezzo delle azioni stabile: 2005 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 5% ) di 2005 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1999	5,800	Jiguang Qu	www.ssygroup.com.hk

SSY Group Limited, una holding di investimento, ricerca, sviluppa, produce, commercializza e vende vari prodotti farmaceutici a ospedali e distributori nella Repubblica Popolare Cinese e a livello internazionale. L'azienda offre soluzioni per infusione endovenosa, tra cui sacche morbide non in PVC, sacche morbide verticali, flaconi di plastica PP e bottiglie di vetro, nonché iniezioni in fiale. Fornisce anche iniezioni di piccolo volume, preparazioni orali, preparazioni di medicina cinese e preparazioni biologiche, oltre a prodotti farmaceutici sfusi e materiali medici.

SSY Group Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di SSY Group con la sua capitalizzazione di mercato?
2005 statistiche fondamentali
Capitalizzazione di mercato	HK$11.18b
Guadagni(TTM)	HK$1.37b
Ricavi(TTM)	HK$6.47b

8.2x

Rapporto P/E

1.7x

Rapporto P/S

2005 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2005 Conto economico (TTM)
Ricavi	HK$6.47b
Costo del fatturato	HK$2.95b
Profitto lordo	HK$3.52b
Altre spese	HK$2.15b
Guadagni	HK$1.37b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.46
Margine lordo	54.39%
Margine di profitto netto	21.11%
Rapporto debito/patrimonio netto	47.7%

Come si è comportato 2005 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

4.8%

Rendimento attuale del dividendo

39%

Rapporto di remunerazione

2005 Panoramica delle azioni

Premi

Analisi del rischio

SSY Group Limited Concorrenti

SEHK:2186

HK$10.1b

SEHK:719

HK$9.6b

SEHK:570

HK$11.6b

SEHK:512

HK$16.1b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Chairman & CEO recently bought HK$4.8m worth of stock

Recent updates

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Chairman & CEO recently bought HK$4.8m worth of stock

Analysts Just Slashed Their SSY Group Limited (HKG:2005) EPS Numbers

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$1.5m worth of stock

Consensus EPS estimates fall by 10%

Price target decreased by 10% to HK$5.58

SSY Group Limited Announces Update on Product Development

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group's (HKG:2005) Dividend Will Be HK$0.08

First half dividend increased to HK$0.08

SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited's (HKG:2005) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 16%

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

Upcoming dividend of HK$0.10 per share

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

SSY Group Limited Provides Update on Product Development

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Chairman & CEO recently bought HK$2.5m worth of stock

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock

SSY Group Limited Announces Update on Product Development